Crystalline tromethamine salt of bimatoprost acid prevents precipitation in ocular solutions, maintaining drug potency and bioavailability.
Boronate ester compounds maintain proteasome inhibition while preventing cyclic trimeric anhydride formation and air-sensitivity.
Novel water-soluble cyclosporin analogs inhibit cyclophilin to treat ocular conditions.
Segmented crosslinking enables sprayable chitosan application while preventing premature runoff from treatment sites.
A recombinant fusion protein links SIRPα to VEGFR1 via an Fc fragment to bind CD47 and VEGF simultaneously.
Imidazolo-, oxazolo-, and thiazolopyrimidine derivatives modulate TRPV1 activity.
Amide-substituted indazole salts resolve weak inhibitory activity and off-target effects by achieving high selectivity for BRCA-deficient cancer cells.
Fused pentacyclic imidazole derivatives neutralize TNFα signaling while minimizing adverse cardiovascular side-effects and metabolic clearance.
Selective FXR agonists resolve the trade-off between efficacy and selectivity by optimizing molecular structures to improve lipid profiles.
Bovine trypsin converts single-chain clostridial neurotoxins into di-chain forms for downstream purification.
Novel oxo-substituted boronic acid compound inhibits beta-lactamases through specific molecular structure.
Slow-release L-cysteine capsules bind acetaldehyde in the stomach, preventing local histamine release that causes facial redness and hypersensitivity.
Stable thiazole inner salt monohydrate breaks down advanced glycation end products.
Intravitreal MLPSC injections protect photoreceptors and reduce inflammation, improving visual acuity beyond anti-VEGF neovascularization control.